Page last updated: 2024-12-05

5,5-dimethylhydantoin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5,5-dimethylhydantoin: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6491
CHEMBL ID3181806
CHEBI ID183672
SCHEMBL ID22069
MeSH IDM0096712

Synonyms (64)

Synonym
5,5-dimethyl-imidazolidine-2,4-dione
dm hydantoin
wln: t5mvmv ehj e1 e1
nsc-8652
nsc8652
dantoin dmh
77-71-4
dimethylhydantoin
5,5-dimethylhydantoin
2,4-imidazolidinedione, 5,5-dimethyl-
hydantoin, 5,5-dimethyl-
5,5-dimethylimidazolidine-2,4-dione
inchi=1/c5h8n2o2/c1-5(2)3(8)6-4(9)7-5/h1-2h3,(h2,6,7,8,9
ai3-61127
5,5-dimethyl-2,4-imidazolidinedione
dantoin 736
brn 0002827
einecs 201-051-3
hsdb 5216
nsc 8652
5,5-dimethyl hydantoin
5,5-dimethylhydantoin, 97%
D0739
CHEBI:183672
AKOS000120928
A839172
5,5-dimethyl-2,4-imidazolidinedione; 5,5-dimethylimidazolidine-2,4-dione
NCGC00248006-02
NCGC00248006-01
unii-34032mq9ro
5-24-05-00348 (beilstein handbook reference)
34032mq9ro ,
ec 201-051-3
STK532811
tox21_202049
NCGC00259598-01
dtxcid601754
tox21_300361
cas-77-71-4
dtxsid5021754 ,
NCGC00254403-01
BBL010734
FT-0619787
5,5-dimethyl hydantoin [hsdb]
dm hydantoin [inci]
SCHEMBL22069
5,5-dimethyl-hydantoin
4,4-dimethyl-2,5-dioxoimidazolidine
Q-200523
5,5-dimethyl-imidazolidin-2,4-dion
5,5-dimethylimidazolidin-2,4-dione
5,5-dimethyl-imidazolidin-2,4-dione
STR04524
CHEMBL3181806 ,
mfcd00005266
F1908-0098
D77989
bdbm50182427
n,n,n,n-tetrabenzyl-p-phenylenediamine
5,5-dimethylhydantoin; lc-tdda; ce10
EN300-16759
Q27256302
CS-W011134
Z56766998
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
imidazolidine-2,4-dioneAn imidazolidinone with oxo groups at position 2 and 4.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency31.70020.003041.611522,387.1992AID1159555
estrogen nuclear receptor alphaHomo sapiens (human)Potency63.77780.000229.305416,493.5996AID743069
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency52.75150.000627.21521,122.0200AID743219
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Platelet-activating factor acetylhydrolaseHomo sapiens (human)IC50 (µMol)1,000.00000.00000.38373.9000AID1308821
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (9)

Processvia Protein(s)Taxonomy
peptide hormone processingPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
low-density lipoprotein particle remodelingPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
lipid oxidationPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
plasma lipoprotein particle oxidationPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
phosphatidylcholine catabolic processPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
platelet activating factor metabolic processPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
positive regulation of inflammatory responsePlatelet-activating factor acetylhydrolaseHomo sapiens (human)
platelet activating factor catabolic processPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
positive regulation of monocyte chemotaxisPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
1-alkyl-2-acetylglycerophosphocholine esterase activityPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
phospholipid bindingPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
hydrolase activity, acting on ester bondsPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
calcium-independent phospholipase A2 activityPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
extracellular regionPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
low-density lipoprotein particlePlatelet-activating factor acetylhydrolaseHomo sapiens (human)
high-density lipoprotein particlePlatelet-activating factor acetylhydrolaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1308821Inhibition of human recombinant Lp-PLA2 using PED6 as substrate preincubated for 30 mins followed by substrate addition measured for 20 mins by fluorescence assay2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Discovered through X-ray Fragment Screening.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (38.89)18.7374
1990's0 (0.00)18.2507
2000's2 (11.11)29.6817
2010's8 (44.44)24.3611
2020's1 (5.56)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 43.95

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index43.95 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index5.00 (4.65)
Search Engine Demand Index60.97 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (43.95)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]